Clinical Trial Results:
Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lymphoma (DLBCL) patients.
Summary
|
|
EudraCT number |
2015-005273-20 |
Trial protocol |
IT |
Global end of trial date |
17 Feb 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Oct 2022
|
First version publication date |
11 Oct 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
FIL-GALILEO
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02670317 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Fondazione Italiana Linfomi (FIL) ONLUS
|
||
Sponsor organisation address |
Piazza Turati 5, Alessandria, Italy,
|
||
Public contact |
Segreteria, Fondazione Italiana Linfomi Onlus, +39 0131/033151, segreteriadirezione@filinf.it
|
||
Scientific contact |
Segreteria, Fondazione Italiana Linfomi Onlus, +39 0131/033151, segreteriadirezione@filinf.it
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
03 Oct 2019
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
17 Feb 2017
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate the efficacy of G-CHOP-21 in combination with Ibrutinib in terms of 2-yrs PFS; To evaluate the safety of G-CHOP-21 in combination with Ibrutinib (extra-hematologic toxicity = grade 3 or treatment interruption for safety reasons or any toxic death during the 6 cycles of treatment).
|
||
Protection of trial subjects |
A subject must be discontinued from study treatment in case of:
- completed treatment as per protocol
- Patient withdraw consent to participate
- the investigator believes that for safety reasons it is in the best interest of the subject to discontinue the treatment
- disease progression at any time
- occurrence of an unacceptable adverse event (> grade 3 toxicity for > 2 weeks)
If the treatment is discontinued for more than 3 weeks patient is withdrawn from study protocol treatment.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
02 Sep 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Italy: 1
|
||
Worldwide total number of subjects |
1
|
||
EEA total number of subjects |
1
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
1
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
One patient recruited in Italy from September 2, 2016, with date of last completed February 17, 2017 (date of early closure of study). | ||||||
Pre-assignment
|
|||||||
Screening details |
Patients (18-60 years) with poor-prognosis (age-adjusted International Prognostic Index, aaIPI, 2 or 3) newly diagnosed DLBCL. All patients must satisfy all the inclusion criteria and none of exclusion criteria. | ||||||
Period 1
|
|||||||
Period 1 title |
Baseline (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Single arm | ||||||
Arm description |
One single arm. Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib. | ||||||
Arm type |
Single arm study | ||||||
Investigational medicinal product name |
Ibrutinib
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Capsule
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
560 mg (4 x 140mg capsules) per os (PO) QD, day 1-126 once daily
|
||||||
Investigational medicinal product name |
Obinutuzumab (G)
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Concentrate for solution for infusion
|
||||||
Routes of administration |
Intravenous use
|
||||||
Dosage and administration details |
1000 mg, intra venous (IV) days 1, 8, 15, 21, 42, 63, 84, 105, 126,147.
It is allowed to split the first Obinutuzumab infusion over 2 days (day 1 and 2) if the patient is at increased risk for infusion related reaction (IRR) (high tumor burden, high peripheral lymphocyte count or other medical conditions).
|
||||||
Investigational medicinal product name |
Cyclophosphamide
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Powder for infusion
|
||||||
Routes of administration |
Intravenous use
|
||||||
Dosage and administration details |
Cyclophosphamide: 750 mg/m2, IV on day 1
CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) will be administered according to the standard preparation and infusion procedures at each investigational site and at least 30 minutes after the Obinutuzumab infusion. CHOP-21: days 1, 21, 42, 63, 84, 105
|
||||||
Investigational medicinal product name |
Adriamycin
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Solution for injection/infusion
|
||||||
Routes of administration |
Intravenous use
|
||||||
Dosage and administration details |
Adriamycin: 50 mg/m2, IV on day 1
CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) will be administered according to the standard preparation and infusion procedures at each investigational site and at least 30 minutes after the Obinutuzumab infusion. CHOP-21: days 1, 21, 42, 63, 84, 105
|
||||||
Investigational medicinal product name |
Vincristine
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Solution for injection/infusion
|
||||||
Routes of administration |
Intravenous use
|
||||||
Dosage and administration details |
Vincristine: 1.4 mg/m2, IV on day 1, (max 2 mg)
CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) will be administered according to the standard preparation and infusion procedures at each investigational site and at least 30 minutes after the Obinutuzumab infusion. CHOP-21: days 1, 21, 42, 63, 84, 105
|
||||||
Investigational medicinal product name |
Prednisone
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Prednisone: 100 mg/day, PO on day 1-5
CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) will be administered according to the standard preparation and infusion procedures at each investigational site and at least 30 minutes after the Obinutuzumab infusion. CHOP-21: days 1, 21, 42, 63, 84, 105
|
||||||
|
|
|||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||
Reporting group title |
Baseline
|
||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Single arm
|
||
Reporting group description |
One single arm. Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib. |
|
|||||||||
End point title |
Progression Free Survival (PFS) [1] | ||||||||
End point description |
PFS will be defined as the time between the date of enrolment and the date of disease progression, relapse or death from any cause.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
2 years
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only one patient was enrolled, the study is officially closed by 17/2/2017. Analyzes not carried out. |
|||||||||
|
|||||||||
Notes [2] - Only one patient was enrolled,the study is officially closed by 17/2/2017. Analyzes not carried out |
|||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Clinical relevant toxicity [3] | ||||||
End point description |
To evaluate the safety of G-CHOP-21 in combination with Ibrutinib in terms of proportion of patients experiencing grade 3 or greater extrahematologic toxicity or treatment interruption for safety reasons or any toxic death during the 6 cycles of treatment.
Clinical relevant toxicity will be defined as the proportion of patients experiencing a grade 3 or greater extra-hematologic toxicity or treatment interruption for safety reasons due to patient or clinical decisions or any toxic death during the 6 cycles of treatment.
|
||||||
End point type |
Primary
|
||||||
End point timeframe |
5 months of treatment
|
||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only one patient was enrolled, the study is officially closed by 17/2/2017. Analyzes not carried out. |
|||||||
|
|||||||
Notes [4] - Only one patient was enrolled,the study is officially closed by 17/2/2017. Analyzes not carried out. |
|||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||
Timeframe for reporting adverse events |
2 years
|
||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||
Dictionary name |
CTCAE | ||||||||||||||||||||||
Dictionary version |
4.0
|
||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||
Reporting group title |
Single arm
|
||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||
|
|||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? No | |||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |